Caribou Biosciences to shut down after failed funding for CAR-T trial

Caribou Biosciences, co-founded by Jennifer Doudna, is ceasing operations after failing to secure financing for a late-stage trial of its allogeneic CAR-T therapy for lymphoma. The shutdown reflects ongoing capital constraints in the biotech sector, particularly for cell therapy developers. The company's assets and intellectual property may be sold or licensed, but no buyer has been announced.